L'intérêt à découvert pour Wizz Air Holdings donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Wizz Air Holdings. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Wizz Air Holdings (OTC:WZZZY) Stock, Rapport sur les intérêts à découvert

Wizz Air is a prominent ultralow-cost airline group operating primarily across Europe, the Middle East, North Africa, and Northwest Asia. Founded in 2003, the company offers scheduled short-haul and medium-haul point-to-point flights under the Wizz Air brand. As of March 2024, Wizz Air operated a fleet of 208 aircraft, connecting approximately 200 destinations across 50 countries.

WIZZ AIR HOLDINGS UNS/ADR by Wizz Air Holdings PLC

Wizz Air Holdings PLC

<p><a href="https://www.benzinga.com/digital-assets/livestream" title="https://www.benzinga.com/digital-assets/livestream">https://www.benzinga.com/digital-assets/livestream</a></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Exclusives

Markets

$BTC

Anthony Dixon, Digital Assets Product Manager, FTSE Russell / LSEG Says There Are Liquidity Concerns Some Names Outside Of Bitcoin, Ethereum, Solana

<p><strong>NVIDIA Corp&#8217;s</strong> earnings report <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42048963/why-nvidia-earnings-may-trigger-massive-sp-500-volatility">Wednesday after-hours</a> could have large implications for <strong>Advanced Micro Devices, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), a key competitor in the semiconductor space and a rising player in AI hardware. </p>
<p>Nvidia's dominance in AI chips has set the market's standard, and its performance may either validate or challenge AMD's strategic push into this lucrative area.</p>
<p><strong>What To Know:</strong> AMD has been aggressively targeting the AI accelerator market, launching its MI300 series chips aimed at competing with Nvidia's market-leading GPUs. </p>
<p>A strong Nvidia report, highlighting continued AI demand and robust sales, could bode well for AMD by reinforcing confidence in the sector's growth potential. This would bolster expectations for AMD's forthcoming AI products and validate the company's investments in next-generation AI technologies.</p>
<p>However, a disappointing Nvidia report could raise concerns about market saturation or slowing AI investments, potentially dampening enthusiasm for AMD's own growth narrative. Investors will be particularly attuned to Nvidia's guidance on demand for AI infrastructure, as it directly impacts the opportunity space AMD is trying to penetrate.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/events/24/11/42069387/grant-cardone-calls-himself-a-coward-investor-puts-his-money-in-real-assets">Grant Cardone Calls Himself A &#8216;Coward Investor,&#8217; Puts His Money In &#8216;Real Assets&#8217;</a></strong></p>
<p>AMD also faces the risk of unfavorable comparisons. Nvidia's dominant market share and ability to scale its AI solutions more efficiently may highlight challenges AMD could face in gaining meaningful traction against its rival. </p>
<p>With Nvidia options pricing in significant volatility, AMD's stock could see sympathetic moves as investors reassess AI-related growth across the semiconductor industry.</p>
<p>For AMD, Nvidia's results are not just a benchmark but a critical signal for its trajectory in the competitive AI chip race.</p>
<p><strong>What Else:</strong> AMD shares rose Monday <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42045498/whats-going-on-with-advanced-micro-devices-stock-monday">following its collaboration with IBM</a> to integrate AMD Instinct MI300X accelerators into IBM Cloud, enhancing performance for generative AI and enterprise computing and supporting platforms like Watsonx AI and Red Hat Enterprise Linux.</p>
<p>The accelerators, set for release in 2025, aim to help enterprise clients optimize costs and scalability for AI applications.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42069891/sp-500-to-reach-6500-by-end-of-2025-analysts-predict-could-it-spark-ma-revival">S&amp;P 500 To Reach 6,500 By End Of 2025, Analysts Predict: Could It Spark M&amp;A Revival?</a></strong></p>
<p>Investors can gain exposure to AMD by investing in the <strong>VanEck Semiconductor ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) or the <strong>Invesco QQQ Trust, Series 1</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).</p>
<h2 class="wp-block-heading">Is AMD A Good Stock To Buy?</h2>
<p>Wall Street analysts view Advanced Micro Devices on the whole as an <strong>Outperform</strong>, given the history of coverage over the past three months. <strong>Harsh Kumar</strong> from <strong>Piper Sandler</strong> in Advanced Micro Devices is the most optimistic, expecting a 14.29% rise in the stock in the coming year.</p>
<p>But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Advanced Micro Devices fell 12.95%, which indicates that opinion soured on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 17.57% over the past year.</p>
<p>A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.</p>
<p>AMD has a 52-week high of $227.30 and a 52-week low of $116.37.</p>


What's Going On With AMD Stock?

<p><strong>Cisco Systems Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) shares have fallen 3% to $56.90 following <a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/41981019/cisco-shares-are-dropping-today-whats-going-on">last week&#8217;s release</a> of its fiscal first-quarter 2025 results. </p>
<p>Despite surpassing Wall Street expectations for both revenue and earnings, the company reported a year-over-year revenue decline that raised investor concerns.</p>
<p><strong>What Happened:</strong> Cisco reported quarterly revenue of $13.84 billion, narrowly topping analysts' forecasts of $13.77 billion, with adjusted earnings of 91 cents per share, exceeding the expected 87 cents. </p>
<p>This marked the tenth consecutive quarter the company has outperformed estimates. However, revenue dipped 6% from the prior year, as product revenue fell by 9%, offset slightly by a 6% increase in services revenue.</p>
<p>Cash flow from operations surged 54% year-over-year to $3.7 billion, and Cisco closed the quarter with $18.7 billion in cash and investments. </p>
<p>For the fiscal second quarter, Cisco projected revenue between $13.75 billion and $13.95 billion and adjusted earnings of 89 to 91 cents per share. Full-year revenue guidance was set at $55.3 billion to $56.3 billion, with adjusted earnings of $3.60 to $3.66 per share.</p>
<p><strong>CEO Chuck Robbins</strong> meanwhile emphasized the company&#8217;s strategic position in AI-driven infrastructure investments. Despite the mixed sentiment, several analysts raised price targets on Cisco, with BofA Securities projecting the stock to reach $72.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/events/24/11/42069387/grant-cardone-calls-himself-a-coward-investor-puts-his-money-in-real-assets">Grant Cardone Calls Himself A &#8216;Coward Investor,&#8217; Puts His Money In &#8216;Real Assets&#8217;</a></strong></p>
<h2 class="wp-block-heading">How To Buy CSCO Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Cisco Systems&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CSCO has a 52-week high of $59.38 and a 52-week low of $44.50.</p>


CSCO

What's Going On With Cisco Systems Stock?

<p><a href="https://truthsocial.com/@realDonaldTrump/posts/113511606000227032" title="https://truthsocial.com/@realDonaldTrump/posts/113511606000227032">https://truthsocial.com/@realDonaldTrump/posts/113511606000227032</a></p>


Macro Economic Events

Politics

Economics

General

President-Elect Donald Trump Posts On Truth "I Am Very Pleased To Nominate Dr. Mehmet Oz To Serve As The Centers For Medicare And Medicaid Services (CMS) Administrator..."

Events

Robert Mitchnick, Head of Digital Assets, BlackRock Says We're At Such An Early Stage In The Crypto Education Journey For So Many Different Investor Types

WIIM

NRDY

Nerdy Inc. shares are trading higher following a purchase of shares by CEO Charles K. Cohn.

Robert Mitchnick, Head of Digital Assets, BlackRock Says Inflows Into BlackRock's iShares Bitcoin Trust Options Was Over $1B As Of This Afternoon

Robert Mitchnick, Head of Digital Assets, BlackRock Says A Lot Of The Trends We've Seen This Year Are Probably Well-Positioned To Continue

SYRS

Syros Pharmaceuticals shares are trading higher after falling on Monday after the company announced it gave notice to QIAGEN Manchester of its election to terminate the Master Collaboration Agreement.

Robert Mitchnick, Head of Digital Assets, BlackRock Says If You Look At The Trends In Bitcoin's Dominance, It's Been Pretty Staggering...It's In A Different Category Today Than The Rest Of Crypto

<p>Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 27% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $515,770, and 2 were calls, valued at $88,650.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $210.0 to $290.0 for Alnylam Pharmaceuticals during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Alnylam Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Alnylam Pharmaceuticals's significant trades, within a strike price range of $210.0 to $290.0, over the past month.</p>
<h3>Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732049153_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$240.00</td>
<td>$130.2K</td>
<td align="right">517</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.0</td>
<td>$3.5</td>
<td>$210.00</td>
<td>$62.6K</td>
<td align="right">170</td>
<td align="right">457</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$58.5</td>
<td>$55.9</td>
<td>$57.0</td>
<td>$290.00</td>
<td>$57.0K</td>
<td align="right">241</td>
<td align="right">40</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$54.0</td>
<td>$50.5</td>
<td>$54.0</td>
<td>$250.00</td>
<td>$54.0K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$50.1</td>
<td>$46.6</td>
<td>$48.1</td>
<td>$280.00</td>
<td>$52.9K</td>
<td align="right">395</td>
<td align="right">11</td>
</tr>
</tbody>
</table>
</p>
<h3>About Alnylam Pharmaceuticals</h3>
<p>Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.</p>
<p>In light of the recent options history for Alnylam Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Alnylam Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 446,657, the price of ALNY is up 0.74% at $233.99. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 86 days.</li>
</ul>
<h3>What Analysts Are Saying About Alnylam Pharmaceuticals</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $350.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Alnylam Pharmaceuticals, targeting a price of $384.<br />
&#x2A; An analyst from Piper Sandler downgraded its action to Overweight with a price target of $296.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $400.<br />
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $300.<br />
&#x2A; An analyst from TD Cowen persists with their Buy rating on Alnylam Pharmaceuticals, maintaining a target price of $371. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

ALNY

This Is What Whales Are Betting On Alnylam Pharmaceuticals

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Arista Networks</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ANET, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 30 uncommon options trades for Arista Networks.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 33% bullish and 30%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $342,871, and 21 are calls, for a total amount of $1,005,778.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $260.0 to $460.0 for Arista Networks over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Arista Networks's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Arista Networks's whale trades within a strike price range from $260.0 to $460.0 in the last 30 days. </p>
<h3>Arista Networks Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732049148_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$49.1</td>
<td>$47.5</td>
<td>$48.4</td>
<td>$380.00</td>
<td>$91.9K</td>
<td align="right">110</td>
<td align="right">21</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.3</td>
<td>$14.6</td>
<td>$14.7</td>
<td>$430.00</td>
<td>$80.8K</td>
<td align="right">171</td>
<td align="right">114</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$18.0</td>
<td>$17.4</td>
<td>$17.43</td>
<td>$420.00</td>
<td>$80.3K</td>
<td align="right">309</td>
<td align="right">52</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$2.7</td>
<td>$2.1</td>
<td>$2.45</td>
<td>$460.00</td>
<td>$73.5K</td>
<td align="right">502</td>
<td align="right">311</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$13.3</td>
<td>$12.6</td>
<td>$12.6</td>
<td>$430.00</td>
<td>$69.3K</td>
<td align="right">171</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Arista Networks</h3>
<p>Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.</p>
<p>In light of the recent options history for Arista Networks, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Arista Networks's Current Market Status</h3>
<ul>
<li>With a volume of 2,357,777, the price of ANET is up 1.84% at $377.3. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>Professional Analyst Ratings for Arista Networks</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $424.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Arista Networks with a target price of $495.<br />
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Arista Networks, maintaining a target price of $460.<br />
&#x2A; An analyst from UBS persists with their Neutral rating on Arista Networks, maintaining a target price of $425.<br />
&#x2A; An analyst from Piper Sandler has revised its rating downward to Neutral, adjusting the price target to $421.<br />
&#x2A; Maintaining their stance, an analyst from Rosenblatt continues to hold a Sell rating for Arista Networks, targeting a price of $320. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Arista Networks, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ANET

A Closer Look at Arista Networks's Options Market Dynamics

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Novo Nordisk</strong>.</p>
<p>Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 45 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 40% with bearish.</p>
<p>From the overall spotted trades, 11 are puts, for a total amount of $549,674 and 34, calls, for a total amount of $2,045,493.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $130.0 for Novo Nordisk during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $70.0 to $130.0 in the last 30 days. </p>
<h3>Novo Nordisk Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732049142_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.34</td>
<td>$2.22</td>
<td>$2.23</td>
<td>$115.00</td>
<td>$289.9K</td>
<td>11.2K</td>
<td>3.4K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.66</td>
<td>$105.00</td>
<td>$190.8K</td>
<td>2.1K</td>
<td>557</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$105.00</td>
<td>$152.7K</td>
<td>2.1K</td>
<td>994</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$19.05</td>
<td>$18.8</td>
<td>$18.8</td>
<td>$120.00</td>
<td>$112.8K</td>
<td>1.9K</td>
<td>71</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$4.95</td>
<td>$4.95</td>
<td>$97.50</td>
<td>$99.5K</td>
<td>2.4K</td>
<td>224</td>
</tr>
</tbody>
</table>
</p>
<h3>About Novo Nordisk</h3>
<p>With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.</p>
<p>Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,369,108, the price of NVO is up by 2.64%, reaching $102.44.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>Expert Opinions on Novo Nordisk</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $160.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Novo Nordisk Unusual Options Activity For November 19

SOAR

Volato Group shares are trading higher. The stock may be rising on continued strength after the company recently reported a year-over-year increase in Q3 financial results.

Anthony Dixon, Digital Assets Product Manager, FTSE Russell / LSEG Says Looking Forward, I Think We Can See Some More Elaborate Products In The Crypto Space

Zach Pandl, Managing Director, Research, Grayscale Investments Says Macro Case: The High Inflation, Legacy Of Government Debt, Fragmenting International Monetary System Are What Drives People To Bitcoin

IBRX

ImmunityBio shares are trading higher after the company announced the completion of ANKTIVA's post-approval enrollment of the 100th patient in the BCG unresponsive NMIBC CIS trial. Additionally, D. Boral Capital maintained a Buy rating on the stock.

Interview

Franklin Templeton Research Analyst David Alderman Says Imagines Stablecoins Will Be More Active, Institutional Investors Will Have Easier Access To The Different Types Of Crypto Products They Want

FUTU

Futu Holdings shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results. Also, Citigroup downgraded the stock from Buy to Neutral.

DTCC Digital Assets Executive Director Jennifer O'Rourke Says Just Because Bill Is Passed Into Law Does Not Mean It Is Ready To Go Compliance Wise, There Are Other Procedural Things That Need To Happen Afterwards Including Rule And Commentary Process, Harmonization Between Agencies, Need To Have Deeper Education And Adoption Process By The Market Participants

Comments

Wizz Air Holdings

Intérêt court

Wizz Air Holdings (OTC:WZZZY) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL